Forma Therapeutics and Boehringer Ingelheim Partner to Target Oncology-Relevant Protein-Protein Interactions

Abstract

Forma Therapeutics has landed a 4-year cancer drug discovery deal with Boehringer Ingelheim that is potentially worth up to US$815 M to discover small molecule therapeutics against oncology-relevant protein-protein interactions. With this deal, Boehringer Ingelheim will join Forma’s list of big pharma partners, which includes Roche, Eisai and Novartis.